Jove
Visualize
Contact Us

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of Clinical Trial Enrollment for Pediatric Patients With Hepatoblastoma and Wilms Tumor: A Report From the Children's Oncology Group.

Cancer medicine·2025
Same author

Characteristics of patients with liver tumors deemed ineligible for enrollment on Children's Oncology Group trial AHEP1531: An opportunity to expand inclusion criteria and improve outcome.

Pediatric blood & cancer·2024
Same author

Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database.

EClinicalMedicine·2024
Same author

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.

British journal of haematology·2024
Same author

Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC).

Cancers·2023
Same author

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.

JAMA oncology·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Relapsed hepatoblastoma.

Angela D Trobaugh-Lotrario1, James H Feusner

  • 1Department of Pediatric Hematology/Oncology, Sacred Heart Children's Hospital, Spokane, Washington 99204, USA. angela.trobaugh@providence.org

Pediatric Blood & Cancer
|June 1, 2012
PubMed
Summary

Recurrent hepatoblastoma (HB) treatment primarily involves surgery. Chemotherapy, particularly doxorubicin and irinotecan, shows promise for resectable tumors in relapsed patients.

Area of Science:

  • Pediatric Oncology
  • Hepatoblastoma Research
  • Cancer Therapeutics

Background:

  • Recurrent hepatoblastoma (HB) presents significant treatment challenges.
  • Surgical resection remains the cornerstone of successful HB management.
  • Chemotherapy is utilized to achieve tumor resectability in responsive cases.

Purpose of the Study:

  • To review current therapeutic strategies for recurrent hepatoblastoma.
  • To identify effective chemotherapeutic agents for relapsed HB.
  • To guide future clinical trial design for advanced HB.

Main Methods:

  • Review of existing clinical trial data and literature on recurrent hepatoblastoma.
  • Analysis of chemotherapeutic agent efficacy in phase I/II trials.

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

Related Experiment Videos

Last Updated: May 21, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

  • Evaluation of stem cell transplantation and radiation therapy outcomes.
  • Main Results:

    • Limited responses observed with various chemotherapy regimens in small trials.
    • Doxorubicin (if not previously administered) and irinotecan identified as most active agents.
    • Outcomes for stem cell transplantation and radiation therapy in recurrent HB remain unclear.

    Conclusions:

    • Advances in treating relapsed HB necessitate focused enrollment in phase I/II trials.
    • Prioritizing agents with strong preclinical data is crucial for future therapeutic development.
    • Optimizing treatment for recurrent hepatoblastoma requires further investigation into novel agents and strategies.